Answers are grounded in this paper and cite their sources.
Retrospective study reports improved survival in PCNSL with HD-MTX and whole-brain radiotherapy, highlighting prognostic factors.
Given that most PCNSL cases are diagnosed at a late age, they may be unsuitable for consolidation therapy with autologous stem cell transplantation (HDC-ASCT). We thus examine the outcomes of PCNSL in a multiethnic Asian population treated with HD-MTX-based chemotherapy and consolidation WBRT, so as to benchmark current treatment outcomes. We conducted a retrospective study involving patients (n = 129) diagnosed with PCNSL at the National Cancer Centre Singapore from 2000 to 2019. The median follow-up duration was 47.0 months. Survival analyses were performed using the Kaplan-Meier method and Cox proportional models. The cohort consisted of 76 male and 53 female patients with a median age of 60 years. 85 patients received HD-MTX-based induction therapy as per DeAngelis, while 44 were treated with the Shah protocol. In univariate analyses, male sex, ECOG scores ≥ 1, non-germinal center subtype, use of DeAngelis protocol, and methotrexate dose < 3 g/m2 were significantly correlated with worse PFS and OS. In a multivariate model, the Shah protocol conferred significantly improved outcomes as compared with the DeAngelis protocol for PFS (HR 0.43, 95% CI 0.25–0.73, p = 0.0019) and OS (HR 0.31, 95% CI 0.16–0.59, p = 0.0004). Using gene expression profiling, poor risk PCNSL patients had a higher trend of CD8 T-cells, macrophages and Th-1 cells, upregulation of TIGIT and HAVCR2, and downregulation in WNT11 and CD44. Our study demonstrates that contemporary HD-MTX-based chemoimmunotherapy induction regimens achieve good disease responses in PCNSL. We also highlight significant prognostic factors and a potential role for immunotherapy in PCNSL.
No takes yet. Share an insight, caveat, or question.
Tan et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: